Lumipulse G1200

Whether you’re advancing translational research or supporting late-stage biomarker programs, the LUMIPULSE® G1200 offers a fully automated, high-throughput immunoassay platform designed to deliver sensitive, reliable biomarker data.

KCAS Bio's LUMIPULSE® G1200 instrumentation

The LUMIPULSE® G1200 is a robust, fully automated, CE-marked immunoassay analyzer that we deploy within our LBA technological park to support sponsors across their drug development programs. Using its innovative mono-test cartridge system, the platform enables streamlined workflows, flexible assay implementation, and high operational reliability, while delivering a throughput of up to 120 tests per hour, making it a powerful tool for generating high-quality biomarker data in translational and clinical drug development settings.

What is the CLEIA technology used by the Lumipulse platform?

At the core of the LUMIPULSE platform is chemiluminescent enzyme immunoassay (CLEIA) technology. CLEIA combines highly specific immunochemical reactions with chemiluminescence, where light is emitted as the result of a chemical reaction. By labeling antibodies with chemiluminescent probes, CLEIA enables sensitive and precise detection of a wide range of analytes, including antigens, antibodies, hormones, enzymes, and other biomarkers, while maintaining excellent analytical performance.

At KCAS Bio, we combine technical expertise and capabilities with state-of-the-art operational infrastructure so that we can scale and adapt quickly to the needs of your project.

'Quality by design' drives every aspect of our work. Our facilities, security and IT infrastructure ensure your samples remain protected at all times, while cultivating excellence and innovation among our scientists.

Explore our labs & locations

Xplorer kits and partnership value

Through our collaboration with Fujirebio, we are proud to offer ADxPLORER (Xplorer) immunoassays powered by the LUMIPULSE® G1200 available in our technology park. These Xplorer kits provide sponsors, especially those working on neurological and neurodegenerative biomarkers—with faster access to analytically robust immunoassays beyond early prototypes. By bridging the gap between biomarker discovery and application, this partnership supports confident data generation, accelerates assay development, and ultimately helps drive translational drug development forward.

Did You Know?

Things you didn’t know about the Lumipulse instrument and kits

Did you know that Lumipulse offers a focused neuro and neuroinflammation portfol

The Lumipulse platform provides an extensive neurological biomarker portfolio, covering both CSF and blood-based markers. It ranges from Xplorer kits for emerging biomarkers to Research-Use-Only (RUO) assays for promising markers that may later transition to in vitro diagnostic (IVD) tests once clinical utility is established—such as the plasma Aβ42/Aβ40 ratio, a key marker in Alzheimer’s disease research.

Did you know that Lumipulse kits and instrument deliver highly reliable results?

Lumipulse kits include single-use cartridges with all reagents and integrated controls. In combination with the fully automated Lumipulse G1200 instrument, this setup reduces operator variability and ensures consistent results across runs, users, and sites. Daily multi-level controls monitor performance and detect potential instrument drift. Calibration is based on factory-established master curves, whose stability is verified monthly.
For major neurological markers, intra-assay CVs are typically below 5%, and inter-assay CVs ≤6.2% across multicenter evaluations.

Did you know that Lumipulse competes with ultrasensitive LBA platforms?

Lumipulse reaches low limits of quantification (LLOQs) for plasma and CSF Aβ42, p-tau181/217, and NfL, aligning with “gold-standard” technologies such as Simoa® digital immunoassays and Elecsys® ECLIA platforms.

Did you know that with the Lumipulse, you can test your samples indivually?

There’s no need to run a full 96-well plate when only a few samples require retesting. Because Lumipulse is not plate-based, laboratories aren’t constrained by batch size per run. This is particularly advantageous for retesting or interim analyses, as only the required samples are analyzed, reducing reagent waste and operational costs. Each result is delivered in approximately 35 minutes, and the system can process up to 250–300 tests per day.

Did you know Lumipulse supports clinical tests beyond diagnostic applications?

Beyond initial screening, Lumipulse can help monitor longitudinal biomarker changes related to neuroinflammation (GFAP, sTREM2), neuronal damage (NfL), and neurodegenerative pathways (tau, amyloid beta). These biomarkers are valuable for assessing safety, treatment response, and disease progression during drug development and clinical trials in neurological disorders such as Alzheimer’s disease.